BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15236793)

  • 21. Amyloid-beta aggregation.
    Finder VH; Glockshuber R
    Neurodegener Dis; 2007; 4(1):13-27. PubMed ID: 17429215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's neuroborreliosis with trans-synaptic spread of infection and neurofibrillary tangles derived from intraneuronal spirochetes.
    MacDonald AB
    Med Hypotheses; 2007; 68(4):822-5. PubMed ID: 17055667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain site-specific gene expression analysis in Alzheimer's disease patients.
    Yokota T; Mishra M; Akatsu H; Tani Y; Miyauchi T; Yamamoto T; Kosaka K; Nagai Y; Sawada T; Heese K
    Eur J Clin Invest; 2006 Nov; 36(11):820-30. PubMed ID: 17032350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of cholinesterases in brain and non-brain tumours.
    Vidal CJ
    Chem Biol Interact; 2005 Dec; 157-158():227-32. PubMed ID: 16256970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
    Walton JR
    J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.
    Gouras GK; Almeida CG; Takahashi RH
    Neurobiol Aging; 2005 Oct; 26(9):1235-44. PubMed ID: 16023263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.
    Kar S; Poirier J; Guevara J; Dea D; Hawkes C; Robitaille Y; Quirion R
    Neurobiol Aging; 2006 Feb; 27(2):199-210. PubMed ID: 16399207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
    Pei JJ; Sjögren M; Winblad B
    Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains.
    Wilhelmus MM; Otte-Höller I; Wesseling P; de Waal RM; Boelens WC; Verbeek MM
    Neuropathol Appl Neurobiol; 2006 Apr; 32(2):119-30. PubMed ID: 16599941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in the clinical manifestations of Alzheimer disease pathology.
    Barnes LL; Wilson RS; Bienias JL; Schneider JA; Evans DA; Bennett DA
    Arch Gen Psychiatry; 2005 Jun; 62(6):685-91. PubMed ID: 15939846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model.
    Bharathi ; Shamasundar NM; Sathyanarayana Rao TS; Dhanunjaya Naidu M; Ravid R; Rao KS
    Brain Res Rev; 2006 Sep; 52(2):275-92. PubMed ID: 16782202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOE, vascular pathology, and the AD brain.
    Yip AG; McKee AC; Green RC; Wells J; Young H; Cupples LA; Farrer LA
    Neurology; 2005 Jul; 65(2):259-65. PubMed ID: 16043796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.
    Sugata H; Matsuo K; Nakagawa T; Takahashi M; Mukai H; Ono Y; Maeda K; Akiyama H; Kawamata T
    Neurosci Lett; 2009 Aug; 459(2):96-9. PubMed ID: 19414059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease.
    Lanari A; Amenta F; Silvestrelli G; Tomassoni D; Parnetti L
    Mech Ageing Dev; 2006 Feb; 127(2):158-65. PubMed ID: 16297434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis and Alzheimer's disease.
    Dal Bianco A; Bradl M; Frischer J; Kutzelnigg A; Jellinger K; Lassmann H
    Ann Neurol; 2008 Feb; 63(2):174-83. PubMed ID: 17924575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.
    Woodhouse A; Shepherd CE; Sokolova A; Carroll VL; King AE; Halliday GM; Dickson TC; Vickers JC
    Acta Neuropathol; 2009 Jan; 117(1):19-29. PubMed ID: 19015863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology.
    Blain JF; Aumont N; Théroux L; Dea D; Poirier J
    Eur J Neurosci; 2006 Sep; 24(5):1245-51. PubMed ID: 16965549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metallothionein-I and -III expression in animal models of Alzheimer disease.
    Carrasco J; Adlard P; Cotman C; Quintana A; Penkowa M; Xu F; Van Nostrand WE; Hidalgo J
    Neuroscience; 2006 Dec; 143(4):911-22. PubMed ID: 17027170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput quantification of Alzheimer's disease pathological markers in the post-mortem human brain.
    Byrne UT; Ross JM; Faull RL; Dragunow M
    J Neurosci Methods; 2009 Jan; 176(2):298-309. PubMed ID: 18835409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.